SEARCH RESULT

Total Matching Records found : 1971

Delhi lacks basic services: CAG report-Devjyot Ghoshal and Ruchika Chitravanshi

-The Business Standard CAG state audit report NCT has also unearthed a glaring lack of planning cutting across projects, sectors It may be India's capital city, but behind the New Delhi's storied corridors of power and flush coffers, the metropolis is a difficult mess for the ordinary citizen. The Comptroller and Auditor General's (CAG) state audit report for the National Capital Territory (NCT) of Delhi government has unearthed a series of significant shortcoming...

More »

Novartis patent case: Glivec developer Brian Druker hails SC ruling- Chidanand Rajghatta

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...

More »

In Bastar, CRPF launches a soft offensive to win over villagers-Suvojit Bagchi

-The Hindu   It joins hands with AIIMS to offer health services to villagers Raipur: Maoists as well as security forces have hit upon new strategies to gain an upper hand in the ongoing conflict. The latest one - to check the influence of rebels - has come from the Central Reserve Police Force (CRPF). It is not at all a military manoeuvre, but an offer of medical assistance to villagers in the Maoist-controlled...

More »

Supreme Court rules for cheap cancer drug -Subodh Varma

-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...

More »

Supreme Court's Glivec ruling will ruin innovation

-The Economic Times Extension of life is priceless. Simply priceless." These were the words of Venkat Krishnan (name changed) to Novartis after receiving Treatment with Glivec for about two years. Following his diagnosis with chronic myeloid leukaemia (CML), Venkat married his college sweetheart against the wishes of her family. After all, the prognosis in those days for people suffering from CML was not promising. Taking interferon, a powerful immune therapy, was the...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close